MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/inf.0000000000001623

Медицинская библиотека · The Pediatric infectious disease journal · 2017

Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children: An Open-label, Randomized, Active-controlled, Phase 3 Study.

Dubischar Katrin L, Kadlecek Vera, Sablan Benjamin, Borja-Tabora Charissa Fay, Gatchalian Salvacion, Eder-Lingelbach Susanne, Mueller Zsuzsanna, Westritschnig Kerstin

Клиническое исследование III фазыСтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Japanese encephalitis remains a serious health concern in Asian countries and has sporadically affected pediatric travelers. In the present study, we monitored the safety profile of the Japanese encephalitis virus vaccine IXIARO (Valneva Austria GmbH, Vienna, Austria) in a pediatric population.

METHODS

We randomized 1869 children between 2 months and 17 years of age in an age-stratified manner to vaccination with IXIARO or one of the control vaccines, Prevnar (formerly Wyeth Pharmaceuticals Inc., now Pfizer Inc., Kent, United Kingdom) and HAVRIX 720 (GlaxoSmithKline Biologicals, Rixensart, Belgium). Adverse events (AEs) (unsolicited and solicited local and systemic AEs), serious AEs and medically attended AEs were assessed up to day 56 and month 7 after the first dose.

RESULTS

Incidences of AEs, serious AEs or medically attended AEs did not differ significantly between the groups in any age stratum. AEs were most frequent in children <1 year of age and decreased with age. AEs of special interest, predefined as AEs associated with potential hypersensitivity/allergy or neurologic disorders up to day 56, were reported in 4.6% (IXIARO) versus 6.3% (Prevnar) in the ≥2 months to <1 year age group and 3.4% (IXIARO) versus 3.3% (HAVRIX) in the ≥1 to <18 years age group. Fever, the most frequent systemic reaction in 23.7% of infants to 3.8% of adolescents, decreased with age and did not differ between groups.

CONCLUSIONS

The safety profile of IXIARO was comparable to the control vaccines in terms of overall AE rates, serious AEs and medically attended AEs.

Для цитирования: Dubischar Katrin L, Kadlecek Vera, Sablan Benjamin, Borja-Tabora Charissa Fay, Gatchalian Salvacion, Eder-Lingelbach Susanne, Mueller Zsuzsanna, Westritschnig Kerstin. Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children: An Open-label, Randomized, Active-controlled, Phase 3 Study.. The Pediatric infectious disease journal. 2017. DOI: 10.1097/inf.0000000000001623.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.